COVID-19 in people with rheumatic diseases: risks, outcomes, treatment considerations
The COVID-19 pandemic has brought challenges for people with rheumatic disease in
addition to those faced by the general population, including concerns about higher risks of …
addition to those faced by the general population, including concerns about higher risks of …
Antibody and B cell responses to SARS-CoV-2 infection and vaccination: the end of the beginning
As the COVID-19 pandemic has evolved during the past years, interactions between human
immune systems, rapidly mutating and selected SARS-CoV-2 viral variants, and effective …
immune systems, rapidly mutating and selected SARS-CoV-2 viral variants, and effective …
Outcomes with and without outpatient SARS-CoV-2 treatment for patients with COVID-19 and systemic autoimmune rheumatic diseases: a retrospective cohort study
Background Some patients with systemic autoimmune rheumatic disease and
immunosuppression might still be at risk of severe COVID-19. The effect of outpatient SARS …
immunosuppression might still be at risk of severe COVID-19. The effect of outpatient SARS …
DMARD disruption, rheumatic disease flare, and prolonged COVID-19 symptom duration after acute COVID-19 among patients with rheumatic disease: a prospective …
Objective To describe disease-modifying antirheumatic drug (DMARD) disruption, rheumatic
disease flare/activity, and prolonged COVID-19 symptom duration among COVID-19 …
disease flare/activity, and prolonged COVID-19 symptom duration among COVID-19 …
Breakthrough SARS–CoV‐2 Infections in Patients With Immune‐Mediated Disease Undergoing B Cell–Depleting Therapy: A Retrospective Cohort Analysis
CM Calabrese, E Kirchner, EM Husni… - Arthritis & …, 2022 - Wiley Online Library
Objective Patients with immune‐mediated inflammatory diseases (IMIDs) receiving B cell–
depleting therapy (BCDT) are among the most vulnerable to severe COVID‐19, as well as …
depleting therapy (BCDT) are among the most vulnerable to severe COVID‐19, as well as …
Prolonged COVID-19 symptom duration in people with systemic autoimmune rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance Vaccine …
Objective We investigated prolonged COVID-19 symptom duration, defined as lasting 28
days or longer, among people with systemic autoimmune rheumatic diseases (SARDs) …
days or longer, among people with systemic autoimmune rheumatic diseases (SARDs) …
Effect of DMARDs on the immunogenicity of vaccines
Y van Sleen, KSM van der Geest… - Nature Reviews …, 2023 - nature.com
Vaccines are important for protecting individuals at increased risk of severe infections,
including patients undergoing DMARD therapy. However, DMARD therapy can also …
including patients undergoing DMARD therapy. However, DMARD therapy can also …
COVID-19 infection and hospitalization risk according to vaccination status and DMARD treatment in patients with rheumatoid arthritis
Objectives The objectives of this study were to investigate the incidence of COVID-19
hospitalization in unvaccinated and vaccinated patients with RA compared with matched …
hospitalization in unvaccinated and vaccinated patients with RA compared with matched …
Temporal trends in COVID-19 outcomes among patients with systemic autoimmune rheumatic diseases: from the first wave through the initial Omicron wave
Objectives To investigate temporal trends in incidence and severity of COVID-19 among
patients with systemic autoimmune rheumatic diseases (SARDs) from the first wave through …
patients with systemic autoimmune rheumatic diseases (SARDs) from the first wave through …
Considerations for pharmacologic management of rheumatoid arthritis in the COVID-19 era: a narrative review
R Venkat, ZS Wallace, JA Sparks - Current Rheumatology Reports, 2023 - Springer
Abstract Purpose of Review To review the impact of disease-modifying antirheumatic drugs
(DMARDs) on COVID-19 severity and vaccine immunogenicity and to discuss COVID-19 …
(DMARDs) on COVID-19 severity and vaccine immunogenicity and to discuss COVID-19 …